The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT)
The Diabetes Control and Complications Trial Research Group* Ó Springer-Verlag 1998 Summary In the Diabetes Control and Complications Trial (DCCT), 1441 insulin-dependent diabetic patients in the primary prevention and secondary intervention cohorts were randomly assigned to either conventional or intensive therapy and followed for up to 9 years. Baseline and biennial measurements of autonomic function (R-R variation, Valsalva ratio, and postural testing) as well as quarterly assessment of autonomic symptoms were performed throughout the trial. There were no differences at baseline between patients randomized to intensive vs conventional therapy. In general, autonomic abnormalities increased during the trial; however, R-R variation was less abnormal in the intensively treated secondary intervention (7 % with abnormal results at 4± 6 years) compared with the conventionally treated group (14 % with abnormal results, p = 0.004) and in the combined cohorts (5 % of intensive treatment subjects with abnormal results vs 9 % of conventional treatment subjects, p = 0.0017). There were few abnormal Valsalva ratios or postural tests at baseline or during the trial. No significant difference in Valsalva ratio or postural tests occurred between the intensive and conventional treatment groups. Both the R-R variation and the Valsalva ratio had significantly greater slopes of decline over time in the patients randomized to conventional therapy (1.48 points per year and 0.015 per year, respectively) compared to those randomized to intensive therapy (0.912 points per year and 0.0025 per year). Of the symptoms related to autonomic function, only incomplete bladder emptying was significantly more common in the conventional group. In summary, the DCCT documented that intensive therapy can slow the progression and the development of abnormal autonomic tests. Sy [Diabetologia (1998) [15] . The DCCT used this panel of tests to evaluate the effect of intensive compared to conventional treatment on autonomic nerve function and to determine whether abnormalities of autonomic nerve function could be prevented or their progression slowed.
Subjects and methods
Study design. The DCCT design and methods have been fully described [16] . A primary prevention and a secondary intervention cohort were recruited to test whether intensive diabetes therapy could delay the onset or retard the progression of the major study outcome variable, diabetic retinopathy. At entry, the primary prevention cohort had a duration of IDDM of 1±5 years and, by design, was free of retinopathy by fundus photography and without microalbuminuria (AER £ 40 mg/ 24 h). The secondary intervention cohort had a duration of diabetes of 1±15 years, mild-to-moderate non-proliferative retinopathy, and no more than microalbuminuria ( < 200 mg/24 h). Diabetic neuropathy was neither an inclusion nor an exclusion criterion unless neuropathic symptoms were sufficiently severe in the opinion of the patient or the investigator to merit treatment, in which case it was grounds for exclusion. A total of 1441 subjects were recruited into the two cohorts at 29 centres from 1983 to 1989.
Patients were randomly assigned to either conventional therapy, designed to prevent symptoms of hyper-and hypoglycaemia with one or two injections of insulin per day, or to intensive therapy, designed to maintain near-normal levels of glycaemia. Intensive therapy included frequent (at least 4 per day) self-monitoring of blood glucose and either three or more injections of insulin per day or treatment with an insulin pump, adjusting insulin doses based on glucose levels, diet and exercise. Diabetic complications including neuropathy were assessed at baseline and periodically throughout the trial. Neither the investigator nor the patients were aware of study results unless predetermined safety thresholds were exceeded, at which time appropriate disclosure and treatment were undertaken [16] . The DCCT was terminated in June of 1993 when its external monitoring committee determined that the principal study question had been answered [1] .
Autonomic nervous system (ANS) measurements. Three ANS tests were administered at baseline and biennially thereafter under standardized conditions [17, 18] . Studies were performed in the morning after an overnight (8 h) fast requiring abstinence from food, liquids (except water), caffeine, tobacco products and all medications including over-the-counter medicines. Patients were tested after 30 min of supine rest in a quiet, relaxed atmosphere with the assistance of a timed respiration pacer. Patients who had experienced a hypoglycaemic episode within the past 24 h were rescheduled. Patients were also rescheduled if they had consumed alcohol, engaged in unusually strenuous exercise or experienced severe emotional upset in the previous 24 h, suffered any acute illness in the previous 48 h or taken any insulin in the past 8 h (unless they were on an insulin pump, in which case they maintained the basal infusion rate). Blood glucose level at the time of testing had to be over 2.8 mmol.
R-R variation (heart rate variability), Valsalva manoeuver, and postural testing were recorded at each clinical site and analysed in a central ANS reading centre which has been described elsewhere [18] . Briefly, the data were read into the computer and visually scanned by a technician for quality. The data were edited where necessary, following predetermined rigid guidelines. The specially designed analysis program contained internal checks (sequential vector angle, sequential vector length, rhythm, paced breathing, aberrant cardiac beats, and cross comparison to other analysis techniques) that alerted the analysing technician to possible aberrant data which might not be apparent during visual editing. The data were certified as usable based on whether the study was performed according to the protocol, no cardiac arrhythmia was present, and the patient paced his or her breathing. All studies were reviewed a second time by the director of the reading centre. The data from each centre were obtained by means of specialized monitors prepared specifically for the DCCT by the D. E. Hokanson Co. (Bellevue, Wash., USA).
R-R variation is the measurement of the magnitude of cardiac sinus arrhythmia. This is predominantly (but not exclusively) a function of the parasympathetic nervous system. R-R variation was determined as previously described [19] . The Valsalva ratio was defined as the mean of three R-R intervals after the Valsalva manoeuver (the longest R-R interval and the interval before and after it) divided by the mean of three R-R intervals during the Valsalva manoeuver (the shortest R-R interval and the intervals before and after it) [9, 11] . The Valsalva manoeuver was done twice at each evaluation and the average of the Valsalva ratio for those two tests was used for data analysis. Postural blood pressure testing consisted of two supine measurements of blood pressure at least 6 min apart (generally before and after the R-R variation study), followed by repeated blood pressures at 1, 2, 3, 4, 5 and 10 min after standing.
Abnormal R-R variation was defined as less than 15 and an abnormal Valsalva was a ratio less than 1.50 [14, 21] . Orthostatic hypotension due to autonomic neuropathy was defined as a fall of 10 mm Hg or greater in diastolic blood pressure confirmed by an inadequate catecholamine response to standing [11, 20±22] . A patient was considered to have abnormal ANS measurements if: 1) the R-R variation was less than 15, or 2) the R-R variation was 15±19.9 and the Valsalva ratio was less than 1.50, or 3) orthostatic hypotension confirmed by low catecholamines was present.
Assessment of autonomic symptoms. Every 3 months, subjects were asked about the presence or absence of various neurological symptoms or ailments using a standardized questionnaire. The following classes of symptoms were assessed as present and ascribed to diabetic autonomic neuropathy if the symptom had been present for at least 30 days and could not be attributed to other conditions: postural hypotension, gastroparesis, diabetic diarrhoea, colonic atony, genitourinary symptoms, sudomotor abnormality or hypoglycaemic unawareness [17] .
As previously described [2] , confirmed clinical neuropathy was diagnosed only if definite abnormalities consistent with peripheral sensorimotor neuropathy were detected on the standard exam and were confirmed by abnormal nerve conduction in at least two peripheral nerves or abnormal ANS tests or both.
Statistical analysis. Comparisons of the treatment groups were made using the Wilcoxon rank-sum test for continuous variables and Pearson's chi-squared test for categorical variables. Binary variables were compared with Fisher's exact test. Group differences in the distributions of repeated measures of continuous variables were assessed using the multivariate non-parametric test of stochastic ordering proposed by Lachin [23] , weighting each of the corresponding univariate MannWhitney differences in proportion to the corresponding sample sizes.
The rates of recurrent events (e. g. individual ANS abnormalities) are presented as the number of events per 100 patient-years, calculated as the ratio of the observed number of events to the total number of patient-years of follow-up. The reduction in the event rate in the intensive therapy group is given as 100 %´(1 ± RR), where RR represents the ratio of the crude event rate in the intensive therapy group to that in the conventional therapy group. Confidence intervals for the rate reductions were calculated on log scales after adjusting the variances of the within-group mean rates and their ratio for possible overdispersion [24] , then transformed back to the original scale.
A longitudinal model for R-R variation was fit via the technique of generalized estimating equations [25] . This technique was selected because it accounts for correlated repeated measurements with missing data points. This model was developed from a series of earlier models which were initially fit separately within each treatment group, then combined after eliminating non-significant terms. The covariates that were used in the models were the baseline values of R-R variation, body mass index, age, duration of IDDM, and both systolic and diastolic blood pressure; indicator variables for treatment group, presence of retinopathy at baseline (primary prevention cohort with none compared to secondary intervention cohort with minimal to moderate non-proliferative) and gender; time since randomization (in years); and a time-by-treatment interaction. Separate treatment-specific models were also evaluated to assess the comparability of effects in the two treatment groups.
Except as otherwise noted, results that are nominally significant at the 0.05 level are indicated without formal adjustment for multiple comparisons. Hochberg's improved Bonferroni procedure [26] was used to preserve an overall significance level of 0.05 in the closely related group of tests described in Table  IV . All analyses were conducted under the principle of intention to treat, with all patients included in their originally assigned treatment group.
Results
Baseline characteristics. A summary of selected baseline characteristics of all randomized patients is shown in Table 1 . The differences in characteristics at baseline between the primary prevention and secondary intervention cohorts were expected based on the entrance criteria (e. g. duration of diabetes, presence of microalbuminuria, baseline retinopathy). As previously reported [3] , confirmed clinical neuropathy was higher in the secondary intervention cohort than in the primary prevention cohort (p < 0.04). Similarly the percentage of patients with abnormal R-R variation was higher (p < 0.05) in the secondary inter- Data are mean ± SD or percent a p < 0.04 for total primary prevention vs total secondary intervention b p < 0.05 for total primary prevention vs total secondary intervention vention cohort (Table 1 ). There was no significant difference in Valsalva ratio between the two cohorts. None of the patients in the DCCT had confirmed orthostatic hypotension at baseline. At baseline, there were no significant differences between intensive and conventional treatment groups in either the primary prevention or secondary intervention cohorts, including the presence of autonomic symptoms, except for the symptom of increased urinary volume (intensive = 2.97 % vs conventional = 1.37 %, p = 0.04).
Abnormal ANS test during the DCCT. Table 2 gives the percentage of patients who developed abnormal ANS tests (as defined in ªMethodsº) during the course of the DCCT. The great majority of these abnormalities were cases of low R-R variation; all other types of abnormality remained rare throughout the trial. The relatively small number of events makes it difficult to compare treatment groups or cohorts directly, but two patterns are apparent. Abnormalities are typically more prevalent among patients in the secondary intervention cohort and among patients followed for longer periods; the latter is most readily seen by pooling the data from all four treatment/retinopathy combinations. Figure 1 illustrates the crosssectional prevalence of abnormally low R-R variation. The data used are from the sixth annual evaluation of all patients followed for 6 years or more and the fourth annual evaluation of patients followed for less than 6 years. Abnormally low R-R variation was less prevalent among intensively treated patients in both the primary prevention and secondary intervention cohorts; the difference was statistically significant (p < 0.005) in the secondary intervention cohort, as well as in the pooled data from both cohorts combined (p < 0.002). However, similar comparisons within the smaller groups followed for 8 years or
R-R variation results.
The Diabetes Control and Complications Trial 419 more did not show significant differences (data not shown). Table 3 describes the longitudinal model for R-R variation over time that was fit to these data as described under ªMethodsº above. Results in both treatment groups of both retinopathy cohorts were sufficiently similar to warrant fitting a single model to all DCCT patient results. In addition to R-R variation at baseline, age and duration of IDDM (also measured at baseline) were significant predictors. The slopes of R-R variation over time were negative and significantly different from zero in both treatment groups, indicating a general tendency of R-R variation to decrease with time; but the decrease was significantly slower in the intensive treatment group (0.912 vs 1.477 points per year, p = 0.0004 for the treatment-by-time interaction). Intercept terms differed only negligibly between the two treatment groups, so the model contains no fixed effect for treatment.
It should be noted, though, that most of the limited predictive power of this model (overall R 2 = 39.1 %) is attributable to the patient's R-R variation at baseline: the partial R 2 compared to a model fit from baseline R-R variation alone was only 4.6 %.
Valsalva ratio. Abnormal Valsalva ratios were rare throughout the trial (see Table 2 ). The prevalence of abnormal Valsalva ratios did not differ significantly between treatment groups in either the primary or secondary strata, or even when both strata were pooled (data not shown). The longitudinal model for Valsalva ratio described in Table 3 explained even less of the overall variation than the model for R-R variation (overall R 2 = 27.6 %), and was similarly driven by the baseline value of the response (partial R 2 of 3.4 % compared to a model using baseline Valsalva ratio alone).
In addition to baseline Valsalva ratio, significant predictors included body mass index, duration of IDDM, and a quadratic function of age (all measured at baseline). A fixed effect captured the difference in intercept for intensively treated males compared to men on conventional treatment or women in either treatment group; the intercepts estimated for these other three subgroups were indistinguishable from each other. In addition, Valsalva ratio showed a significant tendency to decrease over time in the conventional group (0.0148 per year, p < 0.0001) but not in the intensive group (estimated slope 0.0025/year, p > 0.6); the difference in slopes between treatment groups was significant at p = 0.0021.
Symptoms. Overall, there were relatively few symptoms consistent with autonomic neuropathy reported by either treatment group and few differences between conventional and intensive groups at the year 5 neurological exam (Table 4) . Weakness on standing, nausea, and incomplete bladder emptying were all Model mean squared error: 0.11975 R -squared: 27.60 % Partial R -squared compared to model using only baseline Valsalva ratio: 3.40 % Models were fit by the technique of generalized estimating equations. Results for the primary prevention and secondary intervention strata were sufficiently similar to justify combining them into a single model more prevalent in the conventionally treated patients (two-sided p values < 0.05). But because of multiple comparisons, only incomplete bladder emptying reached a level which could be considered statistically significant (p = 0.0023). In contrast, decreased awareness of hypoglycaemia was greater in the intensive therapy group (p = 0.0012).
Postural hypotension. Overall, of the more than 6100 examinations for postural hypotension performed during the DCCT, there were 176 abnormal tests (diastolic decrease > 10 mm Hg) in 152 patients. Repeat testing on a separate day revealed that only 38 of these patients experienced a reproducible diastolic drop of more than 10 mm Hg. Catecholamines were analysed in 38 patients, and orthostatic hypotension secondary to autonomic neuropathy (i. e. low catecholamine response) was confirmed in 17. There was no significant treatment group difference in prevalence of confirmed orthostatic hypotension (p = 0.33 for by Fisher's exact test).
Association of autonomic dysfunction with major macrovascular events. Only 12 patients developed major macrovascular events (confirmed myocardial infarction (MI), n = 4; sudden death or death secondary to MI, n = 3); and silent MI or angina pectoris, (n = 5) during the DCCT [27] . In general, there was no association with abnormal autonomic nervous system tests in these 12 individuals. Unfortunately, changes over time intervals bracketing the major macrovascular events were not consistently available due to the nature of the event itself (e. g. death) or the timing of the autonomic tests.
Discussion
The DCCT cohort was a generally young, healthy group of subjects with a relatively short duration of IDDM at baseline. During the 6.5 years average follow-up, the percentage of subjects with abnormal ANS tests nearly doubled. Most of the new abnormalities were declines in R-R variation. It has been previously shown that the Valsalva ratio requires greater parasympathetic impairment before becoming abnormal [28] and natural history studies have shown that postural hypotension is a relatively late finding [29] . The results of the DCCT demonstrate that intensive diabetes therapy prevents, or at least retards the development of abnormal R-R variation and slows the deterioration of R-R variation over time. The generalised estimating equation model suggests that older age, longer duration of diabetes, and greater initial R-R variation were associated with the greatest slopes of deterioration. It has been suggested that other parameters, such as blood pressure, gender and adiposity [31±33] significantly affect R-R variation. The DCCT results did not confirm these crosssectional findings.
There were relatively few subjects who developed more advanced stages of autonomic neuropathy, such as an abnormal Valsalva ratio, orthostatic hypotension or symptoms of autonomic dysfunction. Overall, less than 3 % of DCCT subjects reported symptoms consistent with autonomic dysfunction. Thus, the inability to demonstrate a difference in these rare events between intensive and conventional treatment groups is not surprising.
In the DCCT there was a greater prevalence of hypoglycaemic unawareness in the intensive treatment group, which had a 3-fold greater occurrence of hypoglycaemia compared with the conventional group [34] . This is most likely secondary to changes in the glycaemic threshold for autonomic activation that occurs after hypoglycaemia [35, 36] rather than to autonomic neuropathy.
Previous studies have suggested that R-R variation and Valsalva ratios are often abnormal in patients with coronary artery disease. There were relatively few cardiovascular events in the DCCT and as a result it was not possible to determine the relationship between ANS function and cardiovascular events. However, the follow-up study of the DCCT cohort, The Epidemiology of Diabetes Interventions and Complications (EDIC) study [37] , will be able to examine the putative relationship between ANS function during the DCCT and cardiovascular events.
In summary, as with the other long-term complications of diabetes (sensorimotor neuropathy, nephropathy, and retinopathy), intensive treatment not only prevents the development of abnormal R-R variation, but also slows the deterioration of R-R variation over time.
